PMID- 23688496
OWN - NLM
STAT- MEDLINE
DCOM- 20140210
LR  - 20220311
IS  - 1536-0539 (Electronic)
IS  - 1536-0288 (Linking)
VI  - 27
IP  - 2
DP  - 2013 Jun
TI  - The pharmacoeconomics of breakthrough cancer pain.
PG  - 167-75
LID - 10.3109/15360288.2013.787137 [doi]
AB  - Breakthrough cancer pain (BTP) has a significant impact on patients' activities 
      of daily living, family, and the society; however, the economic ramifications of 
      BTP are largely unknown. This review aims to summarize the available 
      pharmacoeconomics studies of BTP in the context of the availability of several 
      formulations of rapid-onset opioids administered by various routes, which are 
      significantly more expensive than oral opioids. A systematic literature search of 
      PubMed and Tufts registry through August 2012 was conducted using key words 
      including "breakthrough cancer pain" and "cost effectiveness." After exclusion of 
      irrelevant articles, a total of six articles were included. Studies reviewed 
      include two economic survey studies, two quality improvement projects, and two 
      decision-analytic models. These studies demonstrate BTP causes significant 
      financial burden to patients and society through increased hospitalization and 
      health care utilization. Only one study comparing placebo with intranasal 
      fentanyl spray, oral transmucosal fentanyl citrate, and oral transmucosal 
      fentanyl buccal tablet has demonstrated the cost-effectiveness of these 
      rapid-onset opioids for the treatment of BTP. Overall, there is a lack of 
      pharmacoeconomic studies for BTP management with rapid-onset opioids. Further 
      study is warranted assessing the net benefit of rapid-onset opioids to oral 
      opioids to assist decision-making by patients, clinicians, and payers.
FAU - Kuo, Kuan-Ling
AU  - Kuo KL
AD  - Pharmacotherapy Outcomes Research Center and Department of Pharmacotherapy, 
      University of Utah, Salt Lake City, UT 84112, USA.
FAU - Saokaew, Surasak
AU  - Saokaew S
FAU - Stenehjem, David D
AU  - Stenehjem DD
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130520
PL  - England
TA  - J Pain Palliat Care Pharmacother
JT  - Journal of pain & palliative care pharmacotherapy
JID - 101125608
RN  - 0 (Analgesics, Opioid)
RN  - UF599785JZ (Fentanyl)
SB  - IM
MH  - Administration, Buccal
MH  - Administration, Intranasal
MH  - Administration, Oral
MH  - Analgesics, Opioid/administration & dosage/economics/*therapeutic use
MH  - Breakthrough Pain/*drug therapy
MH  - Cost-Benefit Analysis
MH  - Decision Making
MH  - Economics, Pharmaceutical
MH  - Fentanyl/administration & dosage/economics/*therapeutic use
MH  - Hospitalization/economics
MH  - Humans
EDAT- 2013/05/22 06:00
MHDA- 2014/02/11 06:00
CRDT- 2013/05/22 06:00
PHST- 2013/05/22 06:00 [entrez]
PHST- 2013/05/22 06:00 [pubmed]
PHST- 2014/02/11 06:00 [medline]
AID - 10.3109/15360288.2013.787137 [doi]
PST - ppublish
SO  - J Pain Palliat Care Pharmacother. 2013 Jun;27(2):167-75. doi: 
      10.3109/15360288.2013.787137. Epub 2013 May 20.